LSM7 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:51690, HGNC:20470, LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated, LSM7, MIM:607287, NM_016199, NP_057283, XM_017026869, XP_016882358, YNL147W

Omim:OMIM:607287

Id:ENSG00000130332

Hgnc:HGNC:20470

Entrez:51690

Ensembl:ENSG00000130332

Description:LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated

Sm-like proteins were identified in a variety of organisms based on sequence homology with the Sm protein family (see SNRPD2; MIM 601061). Sm-like proteins contain the Sm sequence motif, which consists of 2 regions separated by a linker of variable length that folds as a loop. The Sm-like proteins are thought to form a stable heteromer present in tri-snRNP particles, which are important for pre-mRNA splicing.[supplied by OMIM, Apr 2004]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View LSM7's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with LSM7.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using LSM7.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for LSM7.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with LSM7.

Results found

Linked to

	Label	Description
	GSE131887 5 V 2 DOXYCYCLINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE125956 SYK knockdown 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE133683 1 V 5 DOXORUBICIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 5 V 4 VERTEPORFIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE131887 5 V 2 DOXYCYCLINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE125956 SYK knockdown 4 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE133683 1 V 5 DOXORUBICIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 5 V 4 VERTEPORFIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.